GlassScriptPhysician profile
Amy L Browning
NPI 1457732117
$2,797.02
in general payments reported to CMS, 2019-2025
22 companies · $546 in 2025
The $546 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $742 · 2023: $883 · 2024: $371 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,726 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,725.62 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $722.87 | 2021-2025 | Jakafi, Monjuvi, Monjuvi |
| Astellas Pharma US INC | $259.95 | 2021-2023 | Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $254.70 | 2022-2025 | Livtencity, Iclusig |
| Abbvie INC. | $219.67 | 2022-2025 | |
| Legend Biotech USA INC. | $172.86 | 2024-2025 | Carvykti |
| Inspire Medical Systems, INC. | $166.52 | 2023-2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $166.40 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $147.51 | 2022-2023 | |
| Seagen INC. | $125.81 | 2021-2023 | Adcetris |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2022 | |
| Genmab U.S., INC. | $107.30 | 2023-2024 | Epkinly |
| Karyopharm Therapeutics INC. | $94.86 | 2023-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $50.91 | 2024-2025 | Prevymis, Zerbaxa, Dificid |
| Celgene Corporation | $37.72 | 2022-2023 | Reblozyl |
| Genentech USA, INC. | $26.50 | 2025 | Columvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.45 | 2025 | Vanflyta |
| Shionogi INC | $19.53 | 2023 | Fetroja |
| Servier Pharmaceuticals LLC | $18.18 | 2025 | |
| Beigene USA, INC. | $16.87 | 2023 | Brukinsa |
| Pfizer INC. | $15.89 | 2023 | |
| Agios Pharmaceuticals, INC. | $14.89 | 2023 | Pyrukynd |
| Kadmon Pharmaceuticals LLC | $14.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.